Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Xeophin logo — Pioneering the future of gene therapy with innovative viral...

Xeophin

Pioneering the future of gene therapy with innovative viral vector technologies for scalable and efficient treatments

Founded 2014 Biotechnology

General Information

Company Name Xeophin
Founded Year 2014
Industries Biotechnology
Social

Get notified when Xeophin moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Xeophin

Xeophin is a pioneering biotechnology startup based in Melbourne, Australia, founded in 2014. The company specializes in the future of gene therapy through innovative viral vector technologies for scalable and efficient treatments. Founded by Molloy and Neilson, Xeophin leverages its extensive expertise in large payload, viral vector-based gene therapies, acquired through years of development at Sementis Ltd. At the forefront of advanced gene therapy, Xeophin focuses on large payload, replication incompetent, viral vectors derived from the Pox family of viruses. These therapies are designed for commercial and scalable production in genetically engineered, suspension rescue cell lines. The company employs precise gene editing techniques and rapid prototyping for enhanced efficacy. With a strong focus on the biotechnology industry, Xeophin is poised to revolutionize gene therapy. As the company continues to pioneer innovative solutions, it presents an intriguing opportunity for venture capital firms looking to invest in groundbreaking technologies shaping the future of healthcare.

Taxonomy: Gene Therapy, Viral Vector Technologies, Pox Family of Viruses, Large Payload, Scalable Treatments, Commercialization, Melbourne, Australia, Genetic Engineering, Suspension Rescue Cell Lines, Gene Editing Techniques, Rapid Prototyping

No funding data available for Xeophin yet.

Get notified when Xeophin raises funding

Xeophin Alternatives & Competitors

Xeophin vs
Basilard BioTech, Inc.
Basilard BioTech, Inc. United States

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology
Xeophin vs
Epigenic Therapeutics
Epigenic Therapeutics China

Pioneering Epigenetic Medicine

Series A
13 employees
Biotechnology
Xeophin vs
NewBiologix
NewBiologix Switzerland

Developing technologies for the biopharma industry to allow them to treat the root causes of diseas...

Series A
25 employees
Biotechnology, Health Care

FAQ About Xeophin

Pioneering the future of gene therapy with innovative viral vector technologies for scalable and efficient treatments
Xeophin was founded in 2014.
Xeophin operates in the following industries: Biotechnology.
Top alternatives and competitors to Xeophin include Basilard BioTech, Inc., Epigenic Therapeutics, NewBiologix, PulseSight Therapeutics, Integra Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xeophin and Basilard BioTech, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Xeophin and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy